1333151-91-9

Upstream product

• 1333153-42-6 3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazole 
• 1333154-26-9 (Z)-isopropyl 3-iodoacrylate 
• 1333153-40-4 3-isopropoxy-5-(trifluoromethyl)benzothioamide 
• 1333153-39-1 3-isopropoxy-5-(trifluoromethyl)benzonitrile 
• 149793-69-1 3-fluoro-5-trifluoromethyl-benzonitrile 
• 96088-62-9 isopropyl propiolate 
• 1333153-41-5 methyl 3-isopropoxy-5-(trifluoromethyl)benzimidothioate 
• 1333153-38-0 3-isopropoxy-5-(trifluoromethyl)benzamide 

Downstream Products

• 1333153-57-3 (isobutylcarbonic) (Z)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic anhydride 
• 1333153-58-4 C₁₅H₁₅F₃N₄O₂ 
• 1333152-00-3 (Z)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylonitrile 
• 1333153-86-8 (Z)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid 
• 1333152-11-6 (Z)-pyridin-2-ylmethyl 3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1333152-20-7 (Z)-1-(3,3-difluoroazetidin-1-yl)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)prop-2-en-1-one 

Relevant academic research and scientific papers

METHODS OF PROMOTING WOUND HEALING USING CRM1 INHIBITORS

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g